Preclinical proof-of-concept, analytical development and commercial scale production of lentiviral vector in adherent cells.

Preclinical proof-of-concept, analytical development and commercial scale production of lentiviral vector in adherent cells

Hanna Leinonen, Eevi Lipponen, Anniina Valkama, Heidi Hynynen, Igor Oruetxebarria, Vesa Turkki, Venla Olsson, Jere Kurkipuro, Haritha Samaranayake, Ann-Marie Määttä, Nigel Parker, Seppo Ylä-Herttuala, and Hanna Lesch. Preclinical proof-of-concept, analytical development and commercial scale production of lentiviral vector in adherent cells. 2019 Aug 29; doi: https://doi.org/10.1016/j.omtm.2019.08.006.

Read publication

Cytokines impact natural killer cell phenotype and functionality against glioblastoma in vitro.

Date 28.09.2023

PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification.

Date 26.10.2021

Transcriptomics uncovers substantial variability associated with alterations in manufacturing processes of macrophage cell therapy products.

Date 20.08.2020

Development of large-scale downstream processing for lentiviral vectors.

Date 30.03.2020